Company · CIK 0002007919 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Inhibrx Biosciences, Inc. · INBX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 PForm 4 → | Sep 23, 4:59 pm EDT | Jon Faiz KayyemDirector | 5,000 | $100.00 | $500,000 | 434,360 | +1.16% | |
| Sep 16, 2026 PForm 4 → | Sep 17, 5:46 pm EDT | Jon Faiz KayyemDirector | 5,000 | $100.00 | $500,000 | 429,360 | +1.18% | |
| Sep 11, 2026 SForm 4 → | Sep 15, 5:52 pm EDT | Kimberly ManhardDirector | 1,500 | $109.03 | $163,543 | 7,500 | −16.7% | |
| Sep 8, 2026 SForm 4 → | Sep 10, 7:06 pm EDT | Kimberly ManhardDirector | 1,000 | $115.47 | $115,468 | 9,000 | −10.0% | |
| Sep 8, 2026 PForm 4 → | Sep 8, 5:23 pm EDT | Jon Faiz KayyemDirector | 5,000 | $113.52 | $567,580 | 424,360 | +1.19% | |
| Sep 8, 2026 PForm 4 → | Sep 8, 4:26 pm EDT | Douglas ForsythDirector | 2,500 | $114.65 | $286,617 | 227,064 | +1.11% | |
| Sep 8, 2026 PForm 4 → | Sep 8, 4:04 pm EDT | Mark LappeChief Executive Officer, Director | 25,000 | $105.82 | $2,645,399 | 730,548 | +3.54% |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.